<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Menden, Michael P</style></author><author><style face="normal" font="default" size="100%">Wang, Dennis</style></author><author><style face="normal" font="default" size="100%">Mason, Mike J</style></author><author><style face="normal" font="default" size="100%">Szalai, Bence</style></author><author><style face="normal" font="default" size="100%">Bulusu, Krishna C</style></author><author><style face="normal" font="default" size="100%">Guan, Yuanfang</style></author><author><style face="normal" font="default" size="100%">Yu, Thomas</style></author><author><style face="normal" font="default" size="100%">Kang, Jaewoo</style></author><author><style face="normal" font="default" size="100%">Jeon, Minji</style></author><author><style face="normal" font="default" size="100%">Wolfinger, Russ</style></author><author><style face="normal" font="default" size="100%">Nguyen, Tin</style></author><author><style face="normal" font="default" size="100%">Zaslavskiy, Mikhail</style></author><author><style face="normal" font="default" size="100%">Jang, In Sock</style></author><author><style face="normal" font="default" size="100%">Ghazoui, Zara</style></author><author><style face="normal" font="default" size="100%">Ahsen, Mehmet Eren</style></author><author><style face="normal" font="default" size="100%">Vogel, Robert</style></author><author><style face="normal" font="default" size="100%">Neto, Elias Chaibub</style></author><author><style face="normal" font="default" size="100%">Norman, Thea</style></author><author><style face="normal" font="default" size="100%">Tang, Eric K Y</style></author><author><style face="normal" font="default" size="100%">Garnett, Mathew J</style></author><author><style face="normal" font="default" size="100%">Veroli, Giovanni Y Di</style></author><author><style face="normal" font="default" size="100%">Fawell, Stephen</style></author><author><style face="normal" font="default" size="100%">Stolovitzky, Gustavo</style></author><author><style face="normal" font="default" size="100%">Guinney, Justin</style></author><author><style face="normal" font="default" size="100%">Dry, Jonathan R</style></author><author><style face="normal" font="default" size="100%">Saez-Rodriguez, Julio</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">AstraZeneca-Sanger Drug Combination DREAM Consortium</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Commun</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nat Commun</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">ADAM17 Protein</style></keyword><keyword><style  face="normal" font="default" size="100%">Antineoplastic Combined Chemotherapy Protocols</style></keyword><keyword><style  face="normal" font="default" size="100%">Benchmarking</style></keyword><keyword><style  face="normal" font="default" size="100%">Biomarkers, Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Line, Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Datasets as Topic</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Antagonism</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Resistance, Neoplasm</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Synergism</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Targeted Therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">pharmacogenetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Phosphatidylinositol 3-Kinases</style></keyword><keyword><style  face="normal" font="default" size="100%">Phosphoinositide-3 Kinase Inhibitors</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019 06 17</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">2674</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find optimal patient-specific treatments. Here we report AstraZeneca's large drug combination dataset, consisting of 11,576 experiments from 910 combinations across 85 molecularly characterized cancer cell lines, and results of a DREAM Challenge to evaluate computational strategies for predicting synergistic drug pairs and biomarkers. 160 teams participated to provide a comprehensive methodological development and benchmarking. Winning methods incorporate prior knowledge of drug-target interactions. Synergy is predicted with an accuracy matching biological replicates for &gt;60% of combinations. However, 20% of drug combinations are poorly predicted by all methods. Genomic rationale for synergy predictions are identified, including ADAM17 inhibitor antagonism when combined with PIK3CB/D inhibition contrasting to synergy when combined with other PI3K-pathway inhibitors in PIK3CA mutant cells.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31209238?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fourati, Slim</style></author><author><style face="normal" font="default" size="100%">Talla, Aarthi</style></author><author><style face="normal" font="default" size="100%">Mahmoudian, Mehrad</style></author><author><style face="normal" font="default" size="100%">Burkhart, Joshua G.</style></author><author><style face="normal" font="default" size="100%">Klén, Riku</style></author><author><style face="normal" font="default" size="100%">Henao, Ricardo</style></author><author><style face="normal" font="default" size="100%">Yu, Thomas</style></author><author><style face="normal" font="default" size="100%">Aydın, Zafer</style></author><author><style face="normal" font="default" size="100%">Yeung, Ka Yee</style></author><author><style face="normal" font="default" size="100%">Ahsen, Mehmet Eren</style></author><author><style face="normal" font="default" size="100%">Almugbel, Reem</style></author><author><style face="normal" font="default" size="100%">Jahandideh, Samad</style></author><author><style face="normal" font="default" size="100%">Liang, Xiao</style></author><author><style face="normal" font="default" size="100%">Nordling, Torbjörn E. M.</style></author><author><style face="normal" font="default" size="100%">Shiga, Motoki</style></author><author><style face="normal" font="default" size="100%">Stanescu, Ana</style></author><author><style face="normal" font="default" size="100%">Vogel, Robert</style></author><author><style face="normal" font="default" size="100%">Pandey, Gaurav</style></author><author><style face="normal" font="default" size="100%">Chiu, Christopher</style></author><author><style face="normal" font="default" size="100%">McClain, Micah T.</style></author><author><style face="normal" font="default" size="100%">Woods, Christopher W.</style></author><author><style face="normal" font="default" size="100%">Ginsburg, Geoffrey S.</style></author><author><style face="normal" font="default" size="100%">Elo, Laura L.</style></author><author><style face="normal" font="default" size="100%">Tsalik, Ephraim L.</style></author><author><style face="normal" font="default" size="100%">Mangravite, Lara M.</style></author><author><style face="normal" font="default" size="100%">Sieberts, Solveig K.</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">The Respiratory Viral DREAM Challenge Consortium</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">A crowdsourced analysis to identify ab initio molecular signatures predictive of susceptibility to viral infection</style></title><secondary-title><style face="normal" font="default" size="100%">Nature Communications</style></secondary-title><short-title><style face="normal" font="default" size="100%">Nat Commun</style></short-title></titles><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan-12-2018</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.nature.com/articles/s41467-018-06735-8http://www.nature.com/articles/s41467-018-06735-8.pdfhttp://www.nature.com/articles/s41467-018-06735-8.pdfhttp://www.nature.com/articles/s41467-018-06735-8</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">9</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">1</style></issue></record></records></xml>